Shares of NuVasive, Inc. (NASDAQ:NUVA – Get Rating) have received a consensus rating of "Hold" from the fifteen brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, six have assigned a hold rating and six have issued a buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $61.75.

Several equities analysts recently weighed in on the stock. Morgan Stanley decreased their target price on shares of NuVasive from $62.00 to $54.00 and set an "equal weight" rating for the company in a research note on Friday, July 15th. Canaccord Genuity Group raised their target price on shares of NuVasive from $50.00 to $55.00 in a research note on Friday, August 5th. Piper Sandler decreased their target price on shares of NuVasive from $80.00 to $60.00 and set an "overweight" rating for the company in a research note on Thursday, August 4th. Finally, Truist Financial decreased their target price on shares of NuVasive to $63.00 in a research note on Friday, July 22nd.

NuVasive Price Performance

NASDAQ NUVA opened at $44.44 on Thursday. The company has a quick ratio of 0.70, a current ratio of 1.17 and a debt-to-equity ratio of 0.54. NuVasive has a 12-month low of $41.33 and a 12-month high of $63.46. The company has a market capitalization of $2.31 billion, a PE ratio of -55.55, a price-to-earnings-growth ratio of 1.72 and a beta of 1.18. The firm's 50 day moving average is $48.22 and its 200-day moving average is $51.35.

Institutional Investors Weigh In On NuVasive

A number of hedge funds and other institutional investors have recently modified their holdings of NUVA. Victory Capital Management Inc. lifted its holdings in shares of NuVasive by 1,364.3% during the second quarter. Victory Capital Management Inc. now owns 648,236 shares of the medical device company's stock worth $31,868,000 after buying an additional 603,967 shares in the last quarter. Polar Asset Management Partners Inc. acquired a new position in NuVasive in the first quarter valued at about $27,627,000. Nuance Investments LLC acquired a new position in NuVasive in the first quarter valued at about $22,099,000. Woodline Partners LP raised its stake in NuVasive by 102.6% in the second quarter. Woodline Partners LP now owns 665,010 shares of the medical device company's stock valued at $32,692,000 after purchasing an additional 336,741 shares in the last quarter. Finally, Thrivent Financial for Lutherans raised its stake in NuVasive by 11.4% in the fourth quarter. Thrivent Financial for Lutherans now owns 2,147,399 shares of the medical device company's stock valued at $112,696,000 after purchasing an additional 219,982 shares in the last quarter.

About NuVasive

(Get Rating)

NuVasive, Inc, a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment.

Featured Articles

• Get a free copy of the StockNews.com research report on NuVasive (NUVA)
• This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
• A Trio of Q3 Winners With Room to Run
• Can HCA Healthcare Weather the Normalization?
• Can United Natural Foods Fight Both Inflation and the Fed?
• Mullen Automotive Is Ready To Get In Gear

Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.